¼¼°èÀÇ ´ÙÁß¾Ï ½ºÅ©¸®´× ½ÃÀå : »ê¾÷ ±Ô¸ð, Á¡À¯À², µ¿Çâ, ±âȸ, ¿¹Ãø, °Ë»ç À¯Çüº°, ±â¼úº°, »ùÇú°, ¹æ¹ýº°, ¾Ï À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°, °æÀﺰ(2020-2030³â)
Multicancer Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Technology, By Sample, By Method, By Cancer Type, By Application, By End User, By Region and Competition, 2020-2030F
»óǰÄÚµå : 1728071
¸®¼­Ä¡»ç : TechSci Research
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 189 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,233,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 5,500 £Ü 7,619,000
PDF and Excel (Multi-User License) help
PDF ¹× Excel º¸°í¼­¸¦ ±â¾÷ÀÇ ÆÀÀ̳ª ±â°ü¿¡¼­ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,000 £Ü 11,082,000
PDF and Excel (Custom Research License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù. 80½Ã°£ÀÇ ¾Ö³Î¸®½ºÆ® ŸÀÓÀÌ Æ÷ÇԵǾî ÀÖ°í Copy & Paste °¡´ÉÇÑ PPT ¹öÀüµµ Á¦°øµË´Ï´Ù. ªÀº Bespoke ¸®¼­Ä¡ ÇÁ·ÎÁ§Æ® ¼öÇà¿¡ ¸Â´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ´ÙÁß¾Ï ½ºÅ©¸®´× ½ÃÀåÀº 2024³â 14¾ï 1,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2030³â¿¡´Â 32¾ï 9,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ Áß CAGRÀº 15.12%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

ÀÌ ½ÃÀåÀº Á¶±â ¾Ï °ËÁø¿¡ ´ëÇÑ ÀÎ½Ä Çâ»ó, ´Ù¾çÇÑ ¾Ï À¯ÇüÀÇ ¹ß»ý·ü Áõ°¡, À¯Àüü ºÐ¼® ±â¼úÀÇ ¹ßÀü¿¡ ÈûÀÔ¾î ±Þ¼ÓÈ÷ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀº ¾×ü »ý°Ë, Â÷¼¼´ë ½ÃÄö½Ì(NGS), ´ÙÁß ¾Ï °ËÁøÀ» µ¿½Ã¿¡ °¡´ÉÇÏ°Ô ÇÏ´Â AI ÅëÇÕ »ý¹°Á¤º¸ÇÐ Ç÷§Æû µî ºñħ½ÀÀû Á¶±â °ËÁø ¹æ¹ý¿¡ ´ëÇÑ ÅõÀÚ¸¦ È®´ëÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå °³¿ä
¿¹Ãø ±â°£ 2026-2030³â³â
½ÃÀå ±Ô¸ð(2024³â) 14¾ï 1,000¸¸ ´Þ·¯
½ÃÀå ±Ô¸ð(2030³â) 32¾ï 9,000¸¸ ´Þ·¯
CAGR(2025-2030³â) 15.12%
±Þ¼ºÀå ºÎ¹® ¼ÒÈ­±â
ÃÖ´ë ½ÃÀå ºÏ¹Ì

Á¤ºÎ Áö¿ø ÇÁ·Î±×·¥ ¹× ±¹Á¦ ÀÚ±Ý Áö¿ø ÇÁ·ÎÁ§Æ®´Â ¿¬±¸ ¹× »ó¾÷È­ ¼Óµµ¸¦ ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. Áø´Ü °³¹ß¾÷ü¿Í Çмú ±â°ü °£ÀÇ Àü·«Àû ÆÄÆ®³Ê½ÊÀº °­·ÂÇÑ ÀÓ»ó °ËÁõ°ú ±¤¹üÀ§ÇÑ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ³ë·ÂÀº ¿¹¹æ ÀÇ·á ¹× Àα¸ ¼öÁØ °ËÁø Àü·«À¸·ÎÀÇ Àüȯ°ú °áÇÕµÇ¾î ¼±Áø±¹°ú ½ÅÈï ½ÃÀå ¸ðµÎ¿¡¼­ ´ÙÁß¾Ï Á¶±â °ËÃâ(MCED) °Ë»çÀÇ °­·ÂÇÑ ¼ºÀå µ¿·ÂÀ» âÃâÇϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ

¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡

ÁÖ¿ä ½ÃÀå °úÁ¦

Ç¥ÁØÈ­ ¹× ÀÓ»ó °ËÁõ ºÎÁ·

ÁÖ¿ä ½ÃÀå µ¿Çâ

¾×ü »ý°Ë ¹× À¯Àüü ±â¼úÀÇ ÅëÇÕ

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå °í°´ÀÇ ¸ñ¼Ò¸®

Á¦5Àå ¼¼°èÀÇ ´ÙÁß¾Ï ½ºÅ©¸®´× ½ÃÀå Àü¸Á

Á¦6Àå ºÏ¹ÌÀÇ ´ÙÁß¾Ï ½ºÅ©¸®´× ½ÃÀå Àü¸Á

Á¦7Àå À¯·´ÀÇ ´ÙÁß¾Ï ½ºÅ©¸®´× ½ÃÀå Àü¸Á

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ´ÙÁß¾Ï ½ºÅ©¸®´× ½ÃÀå Àü¸Á

Á¦9Àå ³²¹ÌÀÇ ´ÙÁß¾Ï ½ºÅ©¸®´× ½ÃÀå Àü¸Á

Á¦10Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ´ÙÁß¾Ï ½ºÅ©¸®´× ½ÃÀå Àü¸Á

Á¦11Àå ½ÃÀå ¿ªÇÐ

Á¦12Àå ½ÃÀå µ¿Çâ°ú ¹ßÀü

Á¦13Àå Porter's Five Forces ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

Á¦15Àå Àü·«Àû Á¦¾È

Á¦16Àå ±â¾÷ ¼Ò°³¿Í ¸éÃ¥»çÇ×

HBR
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Multicancer Screening Market was valued at USD 1.41 billion in 2024 and is projected to reach USD 3.29 billion by 2030, registering a CAGR of 15.12% during the forecast period. The market is expanding rapidly, supported by heightened awareness around early cancer detection, growing incidence rates of various cancer types, and technological advancements in genomic analysis. Healthcare systems are increasingly investing in non-invasive early detection methods, including liquid biopsy, next-generation sequencing (NGS), and AI-integrated bioinformatics platforms that facilitate screening for multiple cancers simultaneously.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.41 Billion
Market Size 2030USD 3.29 Billion
CAGR 2025-203015.12%
Fastest Growing SegmentGastrointestinal
Largest MarketNorth America

Government-backed initiatives, such as the Cancer Moonshot program and other international funding projects, are further accelerating research and commercial deployment. Strategic partnerships between diagnostic developers and academic institutions are fostering robust clinical validation and broader adoption. These efforts, combined with the shift toward preventive care and population-level screening strategies, are driving strong momentum for multicancer early detection (MCED) tests in both developed and emerging markets.

Key Market Drivers

Increasing Prevalence of Chronic Diseases

The growing global burden of cancer continues to be a major driver for the multicancer screening market. Rising incidences of cancer types such as breast, lung, colorectal, prostate, and stomach cancer are fueling the demand for comprehensive screening solutions. For example, in 2023 alone, approximately 300,590 new cases of breast cancer were diagnosed in the U.S. According to the World Health Organization, global cancer data from 2020 showed 2.26 million cases of breast cancer, 2.21 million cases of lung cancer, and over 1 million cases each for colon, prostate, skin (non-melanoma), and stomach cancers.

Countries like Denmark, Ireland, and Australia continue to record some of the highest cancer incidence rates globally, indicating a pressing need for early, accurate, and efficient detection methods. Multicancer screening platforms offer the potential to identify a wide array of cancers at earlier stages, improving prognosis and reducing mortality rates. As cancer rates rise, especially in aging and urbanizing populations, the need for reliable MCED solutions will continue to grow, reinforcing market demand.

Key Market Challenges

Lack of Standardization and Clinical Validation

One of the primary challenges faced by the multicancer screening market is the lack of harmonized standards and comprehensive clinical validation for newer screening tests. Despite significant innovation, the absence of universal testing protocols and diagnostic benchmarks across geographies leads to inconsistent results, limiting test reliability. Without standardized procedures, healthcare providers may remain cautious in adopting multicancer screening technologies.

Moreover, many MCED platforms lack validation through large-scale clinical trials, which are essential for establishing clinical efficacy, sensitivity, and specificity. Regulatory agencies demand substantial evidence before approving these tools for widespread use. Without such validation, uncertainty persists regarding the accuracy and practical application of these tests in real-world settings. This slows down market adoption and hinders regulatory acceptance, particularly in diverse population groups with varying risk profiles.

Key Market Trends

Integration of Liquid Biopsy and Genomic Technologies

A prominent trend shaping the multicancer screening landscape is the convergence of liquid biopsy and advanced genomic technologies. Liquid biopsy methods analyze biomarkers such as circulating tumor DNA (ctDNA), RNA, and exosomes from blood or other fluids, offering a minimally invasive approach to early cancer detection. These techniques allow for cancer identification even before symptoms emerge, and they support ongoing disease monitoring and treatment assessment.

When paired with high-throughput genomic tools such as next-generation sequencing (NGS), the accuracy and scope of liquid biopsy expand significantly. NGS enables comprehensive mutation analysis and enhances the detection of multiple cancer types from a single sample. As these technologies become more cost-effective and refined, their adoption is increasing for large-scale, multi-cancer screening. This integration improves test efficiency, reduces patient burden, and supports broader implementation of population-wide cancer detection programs.

Key Market Players

Report Scope

In this report, the Global Multicancer Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Multicancer Screening Market, By Test Type:

Multicancer Screening Market, By Technology:

Multicancer Screening Market, By Sample:

Multicancer Screening Market, By Method:

Multicancer Screening Market, By Cancer Type:

Multicancer Screening Market, By Application:

Multicancer Screening Market, By End User:

Multicancer Screening Market, By Region:

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Multicancer Screening Market.

Available Customizations

Global Multicancer Screening Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Multicancer Screening Market Outlook

6. North America Multicancer Screening Market Outlook

7. Europe Multicancer Screening Market Outlook

8. Asia-Pacific Multicancer Screening Market Outlook

9. South America Multicancer Screening Market Outlook

10. Middle East and Africa Multicancer Screening Market Outlook

11. Market Dynamics

12. Market Trends & Developments

13. Porters Five Forces Analysis

14. Competitive Landscape

15. Strategic Recommendations

16. About Us & Disclaimer

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â